Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;26(4):577-578.
doi: 10.3350/cmh.2020.0143. Epub 2020 Sep 17.

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Jeong Su Park  1 , Soo Han Bae  1
Affiliations
Comment

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Jeong Su Park et al. Clin Mol Hepatol. 2020 Oct.
No abstract available

Keywords: Carcinoma, Hepatocellular; EMT; GSK3β; PI3K inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflict to disclose.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Lee S, Choi EJ, Lee YB, Lee JH, Yu SJ, Yoon JH, et al. Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway. Clin Mol Hepatol. 2020;26:529–539. - PMC - PubMed
    1. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–635. - PMC - PubMed
    1. Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510:407–411. - PMC - PubMed
    1. Ko E, Seo HW, Jung ES, Ju S, Kim BH, Cho H, et al. PI3Kδ is a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;68:2285–2300. - PubMed
    1. Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21:1537–1542. - PMC - PubMed

MeSH terms

Substances

-